Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CADL 8.59
back to 16s--- people hectically bought into the 16.80s after the abstract then the computer killed it.. never before data---- will prevail.
Nice on watch next SINT and THAR rs completed
STSS .64 + 200%
Latest Summations from Friday, 5/24/24
NASI= https://app.screencast.com/vAMm5Tj3CpuKj
NYSI= https://app.screencast.com/lhEr4EbZbMKh2
STSS 14m KUKE YGMZ 14m KIRK11m NUKK 500k COCP 7m SMFL 250k SHIM 2m GDC 8m
trading stocks is as simple as your daily life in and out ...lol aim correctly
catch at the bottom and do not marry emmmmmmmmmmmmmmmm
NCPL hit .15 after hours...HUGE THANKS!
W K H S .19s gtc rebuy filled..niiiice!!
Usually they do those sneaky filings on Friday AFTER close...I always stick around Friday evenings just to make sure no screw jobs hit & I can exit with minimal loss...I'm thankful for your alert as I sold for loss, but could have been worse...I did make a killing on it selling .30's...I'm more green than red on it, but I was positioning for a big move...so gave some back...oh well, moving on to other trades now
yeah, I usually do, but this was sneaky pos move..imo
Why it’s important to read filings, too…
not me, screw me once, I never support/trade again
What seriously fucked up morons...on my DNT list now
Sold it and made a few bucks, will revisit after the dust settles…
NCPL news just out, r/s coming…
N C P L 5x .21's...betting large on it now...this dip is ridiculous on low volumes too...
C X A I, tripled down 2.82, reeks like stop sweep
100% agree, tripled size .23 ;)
MTC .55 bouncing was $12 few days ago
NCPL could go much higher than most anticipate, imo…
NCPL .31 wuuuuuuuut? :)
AKAN 100% reverse split champ today
8-K out Monday on CXAI if you don’t know…
https://www.sec.gov/ix?doc=/Archives/edgar/data/1820875/000182912624003564/cxappinc_8k.htm
Explains why their 10-K and Q1 10-Q are late…
Filled all orders, if they play dirty, I'll just add dips larger...fun stuff!
nibbling back some CXAI 3.70's, but have orders 3.48, 3.55, 3.60
C X A I 4.20's in after hours, scalped half, rebuy larger 3.47...
30 day mortgage delinquencies now at the highest rate since 2020. More homes for sale and vacant then occupied in Austin, Texas area is the new trend. Flippers running out of cash now.
A plethora of ASCO abstracts come out at 5pm today.
It will spark volatility and some substantial moves.
CING .85 Seeking licensing parnters for its Phase 3 adhd medicine -> 3 mill float ran to $13 last year
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
Source: GlobeNewswire Inc.
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it has received confirmation from and is aligned with the U.S. Food and Drug Administration (FDA) on the requirements necessary for filing a New Drug Application (NDA) for its lead Phase 3 candidate CTx-1301 (dexmethylphenidate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients six years of age or older.
Details from the FDA communication to Cingulate include the following:
Per the 505(b)(2) pathway, submission of CTx-1301’s NDA does not require continuation of the fixed dose study and the onset and duration study;
Data collected to date from these two Phase 3 studies will be included in the filing; and
Contemporaneously with the preparation of the NDA filing, Cingulate will conduct a Phase 1 fed/fast study, the study is expected to last approximately two to three weeks, with the results being included in the NDA filing.
“We are pleased with the FDA’s guidance and perspective regarding our pathway to a timely NDA filing, and we will proceed to complete all remaining requirements accordingly,” said Cingulate Chairman and CEO Shane J. Schaffer. “We also believe this communication provides additional go-to-market momentum as we continue to meet with potential partners for the outlicensing of CTx-1301 in the United States and abroad. Now that we have a clear path to submission, we look forward to engaging with key payer stakeholders to achieve maximum access and market penetration to benefit ADHD patients and their families.”
Cingulate has begun NDA preparation and expects to submit its filing in the first half of 2025.
Ann Childress, M.D., President, Center for Psychiatry and Behavior Medicine, Inc., and lead investigator of Cingulate’s CTx-1301 onset and duration study, stated, “The treatment effect size of CTx-1301 was remarkable given the current effect sizes observed in the marketplace. Many patients require longer duration of efficacy and must add a second, or booster, dose to ensure treatment effect over their entire active day. The patients I observed, once notified they were taking CTx-1301, have expressed a desire to remain on the medication after the trial concluded.”
“If approved,” Childress continued, “I believe CTx-1301 could potentially benefit the more than 60 percent of patients currently using immediate-release booster doses to extend the efficacy of their medications.”
Earlier this year, Cingulate presented results from the Phase 3 adult efficacy and safety study of CTx-1301 at the 2024 American Professional Society of ADHD and Related Disorders (APSARD) conference in Orlando, FL.
The results were previously presented at the 2023 Psych Congress, where a poster describing the data was selected as a finalist for the Psych Congress’s First Annual Poster Awards.
The Cingulate poster presented at APSARD provided additional insight regarding CTx-1301’s ADHD leading effect size. Effect size conveys clinical significance rather than statistical significance, is not reliant on sample size, and allows for comparison across trials. The poster presented may be viewed here.
About Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., approximately 6.4 million children and adolescents (11 percent) aged under the age of 18 have been diagnosed with ADHD. Among this group, approximately 80 percent receive treatment, with 65-90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Adult ADHD prevalence is estimated at approximately 11 million patients (4.4 percent), almost double the size of the child and adolescent segment combined. However, only an estimated 20 percent receive treatment.
About CTx-1301
Cingulate’s lead candidate, CTx-1301, utilizes Cingulate’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. While stimulants are the gold standard of ADHD treatment due to their efficacy and safety, the long-standing challenge continues to be providing patients with an entire active-day duration of action. CTx-1301 is designed to precisely deliver three releases of medication at the predefined time, ratio, and style of release to optimize patient care in one tablet. The result is a rapid onset and entire active-day efficacy, with the third dose being released around the time when other extended-release stimulant products begin to wear off.
About Precision Timed Release™ (PTR™) Platform Technology
Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using Cingulate’s innovative PTR drug delivery platform technology. It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release at precise, pre-defined times with no release of drug prior to the intended release. The EBL technology is enrobed around a drug-containing core to give a tablet-in-tablet dose form. It is designed to erode at a controlled rate until eventually the drug is released from the core tablet. The EBL formulation, Oralogik™, is licensed from BDD Pharma. Cingulate intends to utilize its PTR technology to expand and augment its clinical-stage pipeline by identifying and developing additional product candidates in other therapeutic areas in addition to Anxiety and ADHD where one or more active pharmaceutical ingredients need to be delivered several times a day at specific, predefined time intervals and released in a manner that would offer significant improvement over existing therapies. To see Cingulate’s PTR Platform, click here.
About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of attention deficit/hyperactivity disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City. For more information visit Cingulate.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on April 1, 2024. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.
Investor Relations
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301
Matt Kreps
Darrow Associates
mkreps@darrowir.com
214-597-8200
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/00c8b334-57ec-49cf-9a59-02d75463089e
AG big munch 7.04, back in EXK & HYMC
ASNS NEWS+MOONMARKET ALERT
OPGN BSFC JAGX AKAN reverse split watch list
Alabama abolishes capital gains tax on silver and Gold- real money returns posted Sachs Realty on YouTube
Wow, they completely stomped that chart:
https://schrts.co/IeXnrzeQ
FLJ + 50% BKKT AULT .46 … .50s will be back NVDA tomorrow and they printing Bitcoins regularly
$LYRA is definitely due............
Z
V I N E slow load dips, hold tight, month or so out ;)
LMAOOOO, so true!!
LYRA chart is set for this week...stay tuned!
Followers
|
207
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
28526
|
Created
|
01/11/04
|
Type
|
Free
|
Moderator vlispxpert | |||
Assistants dabonenose matt24d K-Pax Natural Trader |
Welcome to Vlispxpert's Underground. This board is mainly for undervalued, oversold stock plays. The price of the stock is not of concern, so .10 to $20+ picks are welcome if they meet the criteria below. (No pinks or otcbb please) I will be placing my watch picks once a week or whenever I find one I really like...These days it's quality over quantity of picks...
Disclaimer:
Anyone who is considering investing in any of my oversold picks, needs to understand that there is usually a reason the stock is oversold in the first place. 9 times out of 10 there was some bad news that caused a major sell off...
These plays are risky in nature because of this factor alone. I am playing the odds when I buy an oversold stock. The theory behind my picks is the price shouldn't go much lower, due to the oversold indicators & the shorts are close to covering. JMHO
If the price does go lower, I average down, which I believe just causes more pressure on the stock rather than relieving pressure by selling. I usually wait for a 25-35% drop before averaging down, depending on the volume & activity of the market.
I also believe in holding the stock through the turbulant bottom when it is trying to correct itself. It may take a day or it may take months, but the theory is, it will turn around at some point...JMHO
There are 4 things that will make me sell a stock immediately:
1) Strong dilution (over 50% addition to O/S).
2) Bankruptcy.
3) Reverse split.
4) Bad news, usually of the financial nature (Big losses, bad quarter, losing major client, etc.)
I just wanted to post this as a reminder to those who do decide to buy one of my picks that there is a high risk factor & that my picks aren't really daytrades. They are buy & hold until the market comes to you. Sometimes they play out like daytrades, and sometimes it's like water drip torture for weeks on end...
I believe in my method, however contrary it is to the daytrade crowd, who wants instant gratification or it's a complete failure in their minds....
Good luck & good trading, I hope this helps in future decisions on buying any future picks...Thanks
Terminology you may hear:
Starter=1%-2% amount to keep eye on stock while it's trying to find support.
Add=2%-6% tripling of position after a 20-35% dip.
Back up Truck=20%-30%
"If you want to get rich, stick your head above the crowd, see which way it is going, and immediately head in the opposite direction" -My Favorite Quote-
"The stock market is a vehicle to move wealth from the impatient to the patient". -Another Great Quote-
My other board strictly for trading gold/silver stocks is located at:
http://investorshub.advfn.com/Beaten-Down-Junior-Gold-and-Silver-Stocks-30266/
Posts Today
|
0
|
Posts (Total)
|
28526
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |